The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC (CoA-CRPC)
Castration-resistant Prostate Cancer
About this trial
This is an interventional treatment trial for Castration-resistant Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
- 18-100 years of age combined use with abiraterone or enzalutamide CRPC
Exclusion Criteria:
- pregnancy acute liver disease or hepatic dysfunction, as determined by levels of alanine aminotransferase (ALT) or aspartate aminotransferase levels (AST) more than 2-fold the upper normal limit nephrotic syndrome or serum creatinine (Cr) ≥2-fold the upper normal limit and creatine phosphokinase (CK) more than 3-fold the upper normal limit primary hypothyroidism psychiatric patients poorly controlled hypertension, as indicated by a Systolic Blood Pressure >180 mmHg or Diastolic Blood Pressure >110 mmHg using contraceptive agent using immunosuppressive drugs, prohibited medication or other non-PCa drugs long-term using CoA drug
Sites / Locations
- Jiangnan UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Experimental: Coenzyme A 200U
Placebo Comparator: Placebo
Coenzyme A 200U per day
Abiraterone without coenzyme A